Ultragenyx Pharmaceutical Inc (RARE)
42.75
-0.45
(-1.04%)
USD |
NASDAQ |
May 03, 16:00
42.79
+0.04
(+0.09%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Cash from Financing (Quarterly): 330.61M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 330.61M |
| September 30, 2023 | 25.23M |
| June 30, 2023 | 33.02M |
| March 31, 2023 | -0.722M |
| December 31, 2022 | 1.882M |
| September 30, 2022 | 491.88M |
| June 30, 2022 | 5.837M |
| March 31, 2022 | 1.612M |
| December 31, 2021 | 85.72M |
| September 30, 2021 | 7.55M |
| June 30, 2021 | 12.63M |
| March 31, 2021 | 12.65M |
| December 31, 2020 | 489.71M |
| September 30, 2020 | 19.14M |
| June 30, 2020 | 35.81M |
| March 31, 2020 | 55.62M |
| December 31, 2019 | 315.44M |
| September 30, 2019 | 0.904M |
| June 30, 2019 | 9.342M |
| March 31, 2019 | 353.62M |
| December 31, 2018 | 12.24M |
| September 30, 2018 | 25.02M |
| Date | Value |
|---|---|
| June 30, 2018 | 13.17M |
| March 31, 2018 | 286.42M |
| December 31, 2017 | 64.44M |
| September 30, 2017 | 1.333M |
| June 30, 2017 | 1.526M |
| March 31, 2017 | 68.97M |
| December 31, 2016 | 74.94M |
| September 30, 2016 | 63.45M |
| June 30, 2016 | -0.025M |
| March 31, 2016 | 0.314M |
| December 31, 2015 | 0.887M |
| September 30, 2015 | 288.65M |
| June 30, 2015 | 2.595M |
| March 31, 2015 | 175.44M |
| December 31, 2014 | 0.412M |
| September 30, 2014 | 60.51M |
| June 30, 2014 | 0.01M |
| March 31, 2014 | 124.04M |
| December 31, 2013 | 0.038M |
| September 30, 2013 | 0.076M |
| June 30, 2013 | 0.056M |
| March 31, 2013 | 0.001M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.722M
Minimum
Mar 2023
491.88M
Maximum
Sep 2022
101.78M
Average
19.14M
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 0.766M |
| Madrigal Pharmaceuticals Inc | 479.92M |
| Sarepta Therapeutics Inc | 22.14M |
| FibroGen Inc | -0.246M |
| Rocket Pharmaceuticals Inc | 0.391M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -83.90M |
| Cash from Investing (Quarterly) | -107.02M |
| Free Cash Flow | -521.57M |
| Free Cash Flow Per Share (Quarterly) | -1.053 |
| Free Cash Flow to Equity (Quarterly) | -85.50M |
| Free Cash Flow to Firm (Quarterly) | -76.98M |
| Free Cash Flow Yield | -16.59% |